Josh Cohen (L) and Justin Klee (Amylyx)
Once held back, Amylyx execs say the FDA is now pushing for an NDA on ALS drug
It turns out the FDA is willing to take a look at Amylyx Pharmaceuticals’ ALS drug after all.
Roughly five months after the FDA said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
